A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS
OBJECTIVES: I. Assess the efficacy and toxicity of etoposide and cisplatin in patients with
recurrent ependymomas.
OUTLINE: All patients receive cisplatin followed by etoposide on days 1-3. Treatment repeats
every 4 weeks for a total of 6 courses unless disease progression or unacceptable toxicity
intervenes. The etoposide dose may be increased by 10% on subsequent courses if the white
blood cell and platelet nadirs on the previous course are at least 3,000 and 100,000,
respectively. Patients are followed every 2 months for 6 months, then every 3 months for 4.5
years.
PROJECTED ACCRUAL: A total of 35 patients will be entered over approximately 7 years if
there are 3-8 responses in the first 13 patients and 7-9 responses in the first 25 patients.
Interventional
Primary Purpose: Treatment
Randolph S. Marks, MD
Study Chair
Mayo Clinic
United States: Federal Government
CDR0000065162
NCT00002876
October 1991
January 2005
Name | Location |
---|---|
Mayo Clinic Scottsdale | Scottsdale, Arizona 85259 |
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
Mayo Clinic Jacksonville | Jacksonville, Florida 32224 |